Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.62−0.06 (-2.24%)
Close on Nov 13, 2026Market cap $91.08MP/E –Yield –
Anixa Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Anixa Biosciences's operating margin for the twelve months ending Oct 31, 2023 was -5243.3%. For fiscal 2024 it was -6586.2%, against -5243.3% the year before. The highest annual figure on record is -10.2% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | -6586.2% | −1342.9 |
| FY2023 | Oct 31, 2023 | -5243.3% | −2677.7 |
| FY2021 | Oct 31, 2021 | -2565.6% | +2190.4 |
| FY2019 | Oct 31, 2019 | -4756.0% | −3471.6 |
| FY2018 | Oct 31, 2018 | -1284.4% | +391.6 |
| FY2017 | Oct 31, 2017 | -1676.0% | −173.0 |
| FY2016 | Oct 31, 2016 | -1503.0% | −1492.8 |
| FY2015 | Oct 31, 2015 | -10.2% | +127.3 |
| FY2014 | Oct 31, 2014 | -137.5% | +1898.6 |
| FY2013 | Oct 31, 2013 | -2036.2% | −1596.3 |
| FY2012 | Oct 31, 2012 | -439.8% | +61.4 |
| FY2011 | Oct 31, 2011 | -501.2% | +217.0 |
| FY2010 | Oct 31, 2010 | -718.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -1219.0% | +327.4 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -756.3% | −569.5 |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | -435.3% | +42.2 |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | -1037.3% | −580.6 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -1546.4% | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -186.8% | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -477.5% | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -456.7% | – |
See a number that looks wrong?